AN2 Therapeutics, a biopharmaceutical company has planned to go public on March 22, 2022. However, it is not seen in any market screener if we search its desired ticker symbol ANTX. The company has a plan to sell four million common shares at $14-$16 meaning that at most $64 million is planned to raise from the public. For sure the collected funds will go to research and development projects so the AN2 could generate stable revenue.
Among clinical-stage biotech firms, AN2 has its Boron technology, a drug discovery platform that initiates based on boron chemistry for research and development projects.
AN2 is developing epetraborole to treat lung disease, Mycobacterium avium complex or MAC. The company has already done with preclinical and clinical phase 1 stage in treatment-refractory MAC for EU and US markets. In Japan, the drug has passed the preclinical stage for now. In other fields, it is undergoing preclinical stages. AN2 is also intending to use the drug in treating non-Tuberculous mycobacterial (NTM) lung disease which is currently hard to fight if it is already penetrated the patient’s lungs.
Perhaps, this week ANTX will go live in mainstream market screeners like Investing, Yahoo Finance, and MarketWatch. Stay alert by bookmarking the ANTX keyword from your search engine.